Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia.
Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H, Ehninger G, Steckel NK, Zander AR, Schwerdtfeger R, Buchholz S, Kolb HJ, Volin L, Fauser A, Polge E, Schmid C, Mohty M, Rocha V. Craddock C, et al. Among authors: greinix h. Leukemia. 2011 May;25(5):808-13. doi: 10.1038/leu.2011.13. Epub 2011 Feb 22. Leukemia. 2011. PMID: 21339758
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation.
Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, Bourquelot P, Greinix H, Frickhofen N, Ringdén O, Zander A, Apperley JF, Gorin C, Borkett K, Schwab G, Goebel M, Russell NH, Gratwohl A. Schmitz N, et al. Among authors: greinix h. Bone Marrow Transplant. 1998 May;21(10):995-1003. doi: 10.1038/sj.bmt.1701234. Bone Marrow Transplant. 1998. PMID: 9632272 Clinical Trial.
Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplants.
Keil F, Prinz E, Kalhs P, Lechner K, Moser K, Schwarzinger I, Jäger U, Fonatsch C, Worel N, Mannhalter C, Rabitsch W, Loidolt H, Schulenburg A, Mitterbauer M, Höcker P, Greinix HT. Keil F, et al. Among authors: greinix ht. Leukemia. 2001 Mar;15(3):355-61. doi: 10.1038/sj.leu.2402048. Leukemia. 2001. PMID: 11237057
Prospective monitoring of minimal residual disease in acute myeloid leukemia with inversion(16) by CBFbeta/MYH11 RT-PCR: implications for a monitoring schedule and for treatment decisions.
Laczika K, Mitterbauer G, Mitterbauer M, Knöbl P, Schwarzinger I, Greinix HT, Rabitsch W, Fonatsch C, Mannhalter C, Lechner K, Jaeger U. Laczika K, et al. Among authors: greinix ht. Leuk Lymphoma. 2001 Sep-Oct;42(5):923-31. doi: 10.3109/10428190109097711. Leuk Lymphoma. 2001. PMID: 11697647 Clinical Trial.
Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome.
Simonitsch-Klupp I, Hauser I, Ott G, Drach J, Ackermann J, Kaufmann J, Weltermann A, Greinix HT, Skrabs C, Dittrich C, Lutz D, Pötter R, Mannhalter C, Lechner K, Chott A, Jaeger U. Simonitsch-Klupp I, et al. Among authors: greinix ht. Leukemia. 2004 Jan;18(1):146-55. doi: 10.1038/sj.leu.2403206. Leukemia. 2004. PMID: 14603341
Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse.
Weltermann A, Fonatsch C, Haas OA, Greinix HT, Kahls P, Mitterbauer G, Jäger U, Kainz B, Geissler K, Valent P, Sperr WR, Knöbl P, Schwarzinger I, Gleiss A, Lechner K. Weltermann A, et al. Among authors: greinix ht. Leukemia. 2004 Feb;18(2):293-302. doi: 10.1038/sj.leu.2403243. Leukemia. 2004. PMID: 14671635
384 results